TOP > 外国特許検索 > METHOD FOR DETECTION OF CANCER, DIAGNOSTIC DRUG AND DIAGNOSTIC KIT FOR CANCER, AND PHARMACEUTICAL COMPOSITION FOR TREATMENT OF CANCER

METHOD FOR DETECTION OF CANCER, DIAGNOSTIC DRUG AND DIAGNOSTIC KIT FOR CANCER, AND PHARMACEUTICAL COMPOSITION FOR TREATMENT OF CANCER

外国特許コード F140007967
整理番号 S2012-1104-C0
掲載日 2014年9月26日
出願国 世界知的所有権機関(WIPO)
国際出願番号 2013JP073194
国際公開番号 WO 2014034798
国際出願日 平成25年8月29日(2013.8.29)
国際公開日 平成26年3月6日(2014.3.6)
優先権データ
  • 特願2012-189224 (2012.8.29) JP
発明の名称 (英語) METHOD FOR DETECTION OF CANCER, DIAGNOSTIC DRUG AND DIAGNOSTIC KIT FOR CANCER, AND PHARMACEUTICAL COMPOSITION FOR TREATMENT OF CANCER
発明の概要(英語) [Problem] The purpose of the present invention is to provide a method for detection of cancer in which samples are easily acquired and measured.
[Solution] This method for detection of cancer comprises the detection of ERO1-Lα proteins in a specimen obtained from a subject, wherein the presence of ERO1-Lα proteins in the specimen indicates the presence of cancer in the subject.
従来技術、競合技術の概要(英語) BACKGROUND ART
Pancreatic cancer includes, known as a poor prognosis in cancer, cancer is one of very difficult to treat. Characteristic symptoms or subjective symptoms difficult to appear, the web is traveling most often found. Therefore, the development of a technique for early detection is desired. In addition, the cancer is pancreatic cancer, surgical resection is attempted in the treatment of a high invasive surgery. Therefore, an alternative to the surgical operation desired to establish.
In addition, the colon cancer, early detection of fecal occult blood test and the like, with early detection by surgery with a high possibility of cancer is radical prostatectomy. Even in the case of relapse after surgery, by excision of early detection and early cure can be sometimes expected. However, the delay in the discovery, in the case of the transition resection difficult, such as anticancer drug treatment or radiation therapy is attempted. However, these therapies may not be necessarily effective, therapeutic methods or the evaluation of the validity a very important role. Therefore, the optimal therapeutic method is selected as an indicator when the desired to establish.
Incidentally, the protein (ERO1-Lα) Endoplasmic Reticulum Oxidoreductin 1 Like α, particularly under a low oxygen environment found as a protein derived from a (non-patent document 1). ERO1-Lα protein, catalyzes the formation of disulfide bonds is known, so that the protein plays an essential role in folding of the (non-patent document 2). However, protein ERO1-Lα, cancer, particularly pancreatic cancer was unknown specific relationship.
  • 出願人(英語)
  • ※2012年7月以前掲載分については米国以外のすべての指定国
  • SAPPORO MEDICAL UNIVERSITY
  • 発明者(英語)
  • TAMURA Yasuaki
  • KUKITA Kazuharu
  • HIROHASHI Yoshihiko
  • TORIGOE Toshihiko
  • SATO Noriyuki
  • KUTOMI Goro
  • KAJIWARA Toshimitsu
  • TANAKA Tsutomu
国際特許分類(IPC)
指定国 National States: AE AG AL AM AO AT AU AZ BA BB BG BH BN BR BW BY BZ CA CH CL CN CO CR CU CZ DE DK DM DO DZ EC EE EG ES FI GB GD GE GH GM GT HN HR HU ID IL IN IS JP KE KG KN KP KR KZ LA LC LK LR LS LT LU LY MA MD ME MG MK MN MW MX MY MZ NA NG NI NO NZ OM PA PE PG PH PL PT QA RO RS RU RW SA SC SD SE SG SK SL SM ST SV SY TH TJ TM TN TR TT TZ UA UG US UZ VC VN ZA ZM ZW
ARIPO: BW GH GM KE LR LS MW MZ NA RW SD SL SZ TZ UG ZM ZW
EAPO: AM AZ BY KG KZ RU TJ TM
EPO: AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR
OAPI: BF BJ CF CG CI CM GA GN GQ GW KM ML MR NE SN TD TG

PAGE TOP

close
close
close
close
close
close